SANGAMO THERAPEUTICS INC
SGMO
SGMO was delisted on the 4th of May, 2026.
210 hedge funds and large institutions have $919M invested in SANGAMO THERAPEUTICS INC in 2018 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 95 increasing their positions, 48 reducing their positions, and 34 closing their positions.
98% more repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 48
12% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 34
1% more funds holding
Funds holding: 208 → 210 (+2)
8% less call options, than puts
Call options by funds: $27.1M | Put options by funds: $29.6M
2.46% less ownership
Funds ownership: 66.25% → 63.79% (-2.5%)
15% less capital invested
Capital invested by funds: $1.09B → $919M (-$167M)
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$25.6M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$25.1M |
| 3 |
BlackRock
New York
|
+$23.1M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$20.3M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$15.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$15.5M |
| 2 |
Prudential Financial
Newark,
New Jersey
|
-$8.22M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$7.13M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$7.07M |
| 5 |
Morgan Stanley
New York
|
-$5.41M |
SGMO Hedge Fund Activity: Q2 2018 in Review
210 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q2 2018, worth a combined $919M — down 15% from $1.09B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new SGMO positions and 34 closed out — a net gain of 4 holders — while 95 added to existing stakes and 48 trimmed.
The largest buyer was State Street, adding an estimated $25.6M. The largest seller was Fidelity Investments, cutting an estimated $15.5M.
- 210 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q2 2018, up from 208 in Q1 2018.
- Funds reported $919M of SANGAMO THERAPEUTICS INC stock for Q2 2018, down 15% quarter-over-quarter.
- 38 funds opened new SANGAMO THERAPEUTICS INC positions in Q2 2018 and 34 closed out, a net change of +4 holders.
- The largest SANGAMO THERAPEUTICS INC buyer in Q2 2018 was State Street, an estimated $25.6M added.
- The largest SANGAMO THERAPEUTICS INC seller in Q2 2018 was Fidelity Investments, an estimated $15.5M sold.
Based on aggregated 13F filings for Q2 2018.